Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Sustained Reductions of Brain Atrophy Observed With S1P Modulator Ozanimod
September 21st 2024In the original phase 3 studies, treatment with ozanimod resulted in significant reductions in clinical relapses and lesion counts on MRI as well as slowed brain volume loss relative to intramuscular interferon-β-1a.
Advancing MOGAD Research: Predictive Markers, Immune Remodeling, and Future Therapies
September 18th 2024In this episode, a pair of neuroimmune experts discussed some of the emerging research for patients with MOGAD, highlighting the need for immunological markers, remodeling therapies, and enhancements to diagnostic criteria. [WATCH TIME: 5 minutes]
Unmet Needs and Challenges Across Pediatric and Adult MOGAD Populations
September 18th 2024The pair of neurologists provided clinical insight on a number of lingering non-treatment unmet needs for patients with MOGAD, including improved care for pediatric patients and underreported complications like sleep disturbances and genitourinary issues in adults. [WATCH TIME: 5 minutes]
Continuing Evolution of MOGAD Diagnosis, Remaining Questions in Antibody Titer Testing
September 16th 2024In this episode, Greenberg and Bennett provide some perspective on the fluidity of MOGAD diagnosis and how it could potentially change over time as more is understood about neuroimmune disorders. [WATCH TIME: 5 minutes]
Navigating MOGAD Diagnosis: Clinical Insights and Key Considerations
September 16th 2024In this segment, the duo of neurologists provided a number of informative considerations treating clinicians should take when diagnosing MOGAD, emphasizing careful testing and interpretation of data in this complex process. [WATCH TIME: 4 minutes]
Gene Therapy RGX-121 Demonstrates Promising Results in Pivotal CAMPSIITE Trial of Hunter Syndrome
September 13th 2024New findings from the CAMPSIITE trial highlight that RGX-121 gene therapy significantly reduces cerebrospinal fluid biomarkers, suggesting its potential as a first treatment for Hunter syndrome.
Patient Dosing Underway for Phase 2 Study of RNA Aptamer BB-031 in Acute Ischemic Stroke
September 12th 2024BB-031 aims to expand the population eligible for acute revascularization therapy by reopening blocked arteries beyond the traditional therapeutic window, potentially increasing eligible AIS patients by nearly 50%.